A Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of SZN-043, a Novel Bispecific Fusion Protein Targeting ASGR1 and ZNRF3/RNF43, in Healthy Volunteers and Subjects with Liver Cirrhosis
A Phase 1b Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of SZN-043 in Participants with Severe Alcohol-Associated Hepatitis
A Phase 1/1b, Three-Part, Randomised, Placebo-Controlled, Single- and Multiple-Ascending-Dose Studyto Evaluate the Safety, Pharmacokinetics, and Activity of SZN-1326 in Healthy Volunteers and in Subjects with Moderate to Severe Ulcerative Colitis
100 Clinical Results associated with Surrozen Operating, Inc.
0 Patents (Medical) associated with Surrozen Operating, Inc.
100 Deals associated with Surrozen Operating, Inc.
100 Translational Medicine associated with Surrozen Operating, Inc.